Palopegteriparatide
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoparathyroidism
Conditions
Hypoparathyroidism
Trial Timeline
Feb 18, 2026 → Jan 1, 2036
NCT ID
NCT07345494About Palopegteriparatide
Palopegteriparatide is a pre-clinical stage product being developed by Ascendis Pharma for Hypoparathyroidism. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07345494. Target conditions include Hypoparathyroidism.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07345494 | Pre-clinical | Recruiting |
| NCT07264634 | Pre-clinical | Recruiting |
Competing Products
9 competing products in Hypoparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| recombinant human somatotropin | Eli Lilly | Pre-clinical | 23 |
| Palopegteriparatide (TransCon PTH) | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| EnteraBio's Oral Parathyroid Hormone (1-34) | Entera Bio | Phase 2 | 44 |
| EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5 | Entera Bio | Phase 1 | 25 |
| EB612 (EBP05) + NATPARA/NATPAR | Entera Bio | Phase 2 | 44 |